Important updates from the American Society of Clinical Psychopharmacology Annual Meeting
Click Here to Manage Email Alerts
Healio Psychiatry has compiled a list of five major stories from the American Society of Clinical Psychopharmacology Annual Meeting.
Insights on COVID-19’s role in revolutionizing telepsychiatry, reasons for reconceptualizing treatment-resistant depression and research on a fatty acid diet for patients with bipolar disorder were among the presentation topics at the virtual meeting.
Which story resonated with you most? Leave a comment or write to us on Twitter @HealioPsych.
How technology and COVID-19 have revolutionized telepsychiatry
Technological advances in the past decade have revolutionized telepsychiatry, which has seen significant changes amid the COVID-19 pandemic, according to Jay Shore, MD, director of telemedicine programming in the department of psychiatry at University of Colorado Anschutz Medical Campus. Read more.
Researchers outline clinical benefits of reconceptualizing treatment-resistant depression
Reconceptualizing treatment-resistant depression as difficult-to-treat depression may have implications for psychiatric research and practice, according to R. Hamish McAllister-Williams, MD, PhD, FRCPsych, of the Institute of Neuroscience at Newcastle University in the U.K., and other presenter. Read more.
Fatty acid diet intervention may stabilize mood among patients with bipolar disorder
A nutrition intervention focused on fatty acids may stabilize mood, energy, irritability and pain among individuals with bipolar disorder, according to Sarah Shahriar, BS, research assistant at The Pennsylvania State University’s Mood Disorders Lab, and colleagues. Read more.
Safety of psilocybin lays groundwork for research in treatment-resistant depression
A psilocybin formulation was well tolerated among healthy patients, which supports research into its use for treatment-resistant depression, according to Hans Eriksson, MD, chief medical officer of COMPASS Pathways, and colleagues. Read more.
Treatments lacking to address impact of irritability on mental health, experts say
Specific treatments are needed to target irritability, according to Manish Jha, MD, assistant professor in the departments of psychiatry and neuroscience at Icahn School of Medicine at Mount Sinai, and colleagues. Read more.